IPP Bureau
Japan nod to Dupixent for children with severe asthma
By IPP Bureau - December 26, 2025
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access
By IPP Bureau - December 26, 2025
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Cipla launches needle-free inhalable insulin Afrezza in India
By IPP Bureau - December 26, 2025
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
Kashiv BioSciences secures Rs. 684 crore funding to build one of India’s largest biopharma facilities
By IPP Bureau - December 26, 2025
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Apollo Pharmacy hits 1,000 stores in Karnataka
By IPP Bureau - December 26, 2025
The opening of our 1000th pharmacy in Karnataka marks an important step
Lunit SCOPE matches pathologist accuracy in HER2 scoring for advanced biliary tract cancer
By IPP Bureau - December 25, 2025
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Tanabe Pharma America transfers RADICAVA business to Shionogi
By IPP Bureau - December 25, 2025
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor
By IPP Bureau - December 25, 2025
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
India's First: Curapod wearable gets Class II nod for drug-free musculoskeletal pain relief
By IPP Bureau - December 24, 2025
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613
By IPP Bureau - December 24, 2025
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
FDA nod to Boehringer Ingelheim’s JASCAYD for progressive pulmonary fibrosis in adults
By IPP Bureau - December 24, 2025
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data
By IPP Bureau - December 24, 2025
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Niagen Bioscience secures full ownership of key NAD+ patents in major IP move
By IPP Bureau - December 24, 2025
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Hansa Biopharma submits FDA application for kidney transplant desensitization treatment
By IPP Bureau - December 24, 2025
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Abbott’s Volt PFA System gets FDA nod
By IPP Bureau - December 24, 2025
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
